News Release

<< Back

Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 22, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced the appointment of Christian Waage to Heron’s Board of Directors.

“Christian’s leadership experience in the biotechnology and healthcare industry along with his transaction experience and specialized regulatory, legal, and financial knowledge will be invaluable to Heron,” commented Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, Inc. “We are thrilled to have Christian join the Heron team, particularly at such a transformative time for the Company.”

Mr. Waage currently serves as Managing Director at Receptos, a wholly owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as Senior Vice President and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Prior to Receptos, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation and licensing operations. Prior to Websense, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner. Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit www.herontx.com.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: the projected sufficiency of our capital position for future periods, the review of the SUSTOL NDA by the FDA, the potential market opportunity for SUSTOL and new products generally, expected timing and acceptance of the SUSTOL commercial launch, the progress in the research and development of HTX-019, HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Source: Heron Therapeutics, Inc.

Investor Relations and Media Contact:
Heron Therapeutics, Inc.
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com